{"id":744935,"date":"2014-09-04T08:00:00","date_gmt":"2014-09-04T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/"},"modified":"2023-03-22T00:04:51","modified_gmt":"2023-03-22T04:04:51","slug":"mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/","title":{"rendered":"Merck\u2019s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the U.S. Food and Drug Administration (FDA) has<br \/>\n      designated relebactam (previously known as MK-7655), the company\u2019s<br \/>\n      investigational beta-lactamase inhibitor, as a Qualified Infectious<br \/>\n      Disease Product (QIDP) with designated Fast Track status. The QIDP and<br \/>\n      Fast Track designations apply to intravenous use of relebactam for the<br \/>\n      treatment of complicated urinary tract infections, complicated<br \/>\n      intra-abdominal infections and hospital-acquired bacterial<br \/>\n      pneumonia\/ventilator-associated bacterial pneumonia.\n    <\/p>\n<p>\n      QIDP designation, provided under the Generating Antibiotic Incentives<br \/>\n      Now (GAIN) Act, offers certain incentives for the development of new<br \/>\n      antibiotics, including a five-year extension of the data exclusivity<br \/>\n      provisions under the Hatch-Waxman Act and priority review of the New<br \/>\n      Drug Application when filed. Fast Track designation provides for<br \/>\n      enhanced communication with the FDA during the drug development program.\n    <\/p>\n<p>\n      \u201cThe lack of new medicines to fight drug-resistant infections is a<br \/>\n      growing public health concern,\u201d said Dr. Nicholas Kartsonis, executive<br \/>\n      director, Infectious Disease, Merck Research Laboratories. \u201cWe are<br \/>\n      pleased that the FDA has designated relebactam as a QIDP with Fast Track<br \/>\n      status, and we look forward to working with the FDA and other experts in<br \/>\n      infectious disease to study this medicine with the goal of bringing it<br \/>\n      to people suffering from potentially life-threatening resistant<br \/>\n      bacterial infections as quickly as possible.\u201d\n    <\/p>\n<p>\n      Beta-lactamases are a family of enzymes produced by some bacteria that<br \/>\n      can cause resistance to several widely used beta-lactam antibiotics,<br \/>\n      including penicillins, cephalosporins and carbapenems. By combining a<br \/>\n      beta-lactamase inhibitor with a beta-lactam antibiotic, it may be<br \/>\n      possible to overcome the resistance and extend the spectrum of activity<br \/>\n      of the antibiotic to fight infections.\n    <\/p>\n<p>\n      Relebactam is an investigational, class A and C, beta-lactamase<br \/>\n      inhibitor that is being evaluated in combination with<br \/>\n      imipenem\/cilastatin in ongoing Phase 2 clinical trials for the treatment<br \/>\n      of complicated urinary tract infections and complicated intra-abdominal<br \/>\n      infections. In preclinical studies, relebactam administered in<br \/>\n      combination with imipenem\/cilastatin demonstrated antibacterial activity<br \/>\n      against a broad range of Gram-negative and beta-lactam-resistant<br \/>\n      pathogens. Merck plans to initiate Phase 3 studies with relebactam in<br \/>\n      combination with imipenem\/cilastatin in 2015.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50936188&#038;newsitemid=20140904005618&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=f53db66b4237093d766c0d507a6d6163\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.twitter%2FMerck&#038;esheet=50936188&#038;newsitemid=20140904005618&#038;lan=en-US&#038;anchor=Twitter&#038;index=2&#038;md5=6a688848c1a0f58d5bc0535cae4620bd\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50936188&#038;newsitemid=20140904005618&#038;lan=en-US&#038;anchor=Facebook&#038;index=3&#038;md5=8aac8ccd732fb9f9e135806f49f36fba\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50936188&#038;newsitemid=20140904005618&#038;lan=en-US&#038;anchor=YouTube&#038;index=4&#038;md5=dd6240e2d15ec37aa2a2a3b2f2800e65\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50936188&#038;newsitemid=20140904005618&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=5&#038;md5=1664dba80e1d3a212e2b381de0fa4c40\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140904005618r1&#038;sid=hq1sc1&#038;distro=nx&#038;lang=en\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Media:<br \/>Caroline Lappetito, 267-305-7639<br \/>or<br \/>Robert        Consalvo, 908-423-6595<br \/>or<br \/>Investors:<br \/>Joseph Romanelli,        908-423-5185<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company\u2019s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia\/ventilator-associated bacterial pneumonia. QIDP designation, provided under the Generating Antibiotic Incentives Now (GAIN) Act, offers certain incentives for the development of new antibiotics, including a five-year extension of the data exclusivity provisions under the Hatch-Waxman Act and priority review of the New Drug Application when filed. Fast Track designation provides for enhanced communication with the FDA during the drug development<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744935","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company\u2019s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia\/ventilator-associated bacterial pneumonia. QIDP designation, provided under the Generating Antibiotic Incentives Now (GAIN) Act, offers certain incentives for the development of new antibiotics, including a five-year extension of the data exclusivity provisions under the Hatch-Waxman Act and priority review of the New Drug Application when filed. Fast Track designation provides for enhanced communication with the FDA during the drug development\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904005618r1&sid=hq1sc1&distro=nx&lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\\\/\",\"name\":\"Merck\u2019s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140904005618r1&sid=hq1sc1&distro=nx&lang=en\",\"datePublished\":\"2014-09-04T08:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140904005618r1&sid=hq1sc1&distro=nx&lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140904005618r1&sid=hq1sc1&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company\u2019s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia\/ventilator-associated bacterial pneumonia. QIDP designation, provided under the Generating Antibiotic Incentives Now (GAIN) Act, offers certain incentives for the development of new antibiotics, including a five-year extension of the data exclusivity provisions under the Hatch-Waxman Act and priority review of the New Drug Application when filed. Fast Track designation provides for enhanced communication with the FDA during the drug development","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:51+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904005618r1&sid=hq1sc1&distro=nx&lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/","name":"Merck\u2019s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904005618r1&sid=hq1sc1&distro=nx&lang=en","datePublished":"2014-09-04T08:00:00+00:00","dateModified":"2023-03-22T04:04:51+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904005618r1&sid=hq1sc1&distro=nx&lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140904005618r1&sid=hq1sc1&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-granted-qualified-infectious-disease-product-qidp-and-fast-track-designations-by-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"80fe78df-e732-49f5-ad9b-5047c680ed58","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744935\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744935"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}